A photo of Richard Graham.

Richard Graham, MD


  • Member, Division of Oncology
  • Assistant Professor, UC Department of Pediatrics
When I treat a person with a brain tumor, I want to help them and their family make the most of their lives.
Richard Graham, MD

About

Biography

As a neuro-oncologist, I specialize in treating brain tumors. When I treat a person with a brain tumor, I want to help them and their family make the most of their lives.

Brain tumors represent a convergence of some of the most important questions in science and some of the most challenging situations in life. New research on the molecular mechanisms underlying the development of tumors is opening up opportunities to target those tumors in ways that haven't been explored yet. At the same time, families impacted by brain tumors find themselves in a situation that can be overwhelmingly unfamiliar and difficult. This exciting research and a desire to help these families is why I chose to be a neuro-oncologist.

In my research, we are trying to use new tools to understand the molecular machinery that makes tumors work so we can target those mechanisms specifically with as little risk as possible to the patient.

My own children remind me that life is too important not to have fun and spend time with the people you love. We don't have any trouble filling our "spare" time!

Services and Specialties

Brain Tumor Center

Research Areas

Oncology

Publications

Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201. Xin, DE; Liao, Y; Rao, R; Ogurek, S; Sengupta, S; Xin, M; Bayat, AE; Seibel, WL; Graham, RT; Koschmann, C; Lu, QR. Neuro-Oncology. 2024; 26:735-748.

BIOL-05. IDENTIFICATION AND VALIDATION OF PA2G4 AS A POTENTIAL THERAPEUTIC TARGET IN PEDIATRIC DIFFUSE GLIOMAS. Sirhan, Z; Sells, BE; Fleming, J; Manring, HR; Graham, RT; McElroy, JP; Haque, SJ; Boué, DR; Becker, AP; Bell, EH; Finlay, J; Chakravarti, A. Neuro-Oncology. 2023; 25:i6.

Multi-institutional analysis of central nervous system germ cell tumors in patients with Down syndrome. Harris, MK; Graham, RT; Cappellano, AM; Margol, AS; Michaiel, G; Crawford, JR; Ioakeim-Ioannidou, M; Stanek, JR; Liu, KX; MacDonald, SM; Abdelbaki, MS. Pediatric Blood and Cancer. 2022; 69:e29830.

GCT-15. Multi-institutional analysis and literature review of central nervous system germ cell tumors in patients with Down syndrome. Harris, MK; Stanek, JR; Graham, RT; Cappellano, AM; Margol, AS; Michaiel, G; Crawford, JR; Liu, KX; MacDonald, SM; Abdelbaki, MS. Neuro-Oncology. 2022; 24:i57-i58.

Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors. Abu-Arja, MH; Osorio, DS; Lassaletta, A; Graham, RT; Coven, SL; Stanek, JR; Bouffet, E; Finlay, JL; Abdelbaki, MS. Pediatric Blood and Cancer. 2022; 69:e29365.

Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients. Graham, RT; Bell, EH; Webb, A; Zhao, Y; Timmers, C; Fleming, JL; Sells, BE; Robison, NJ; Palmer, JD; Finlay, JL; Chakravarti, A. Journal of Pediatric Hematology/Oncology. 2021; 43:e1201-e1204.

Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. Graham, RT; Abu-Arja, MH; Stanek, JR; Cappellano, A; Coleman, C; Chi, S; Cooney, T; Dhall, G; Ellen, JG; Finlay, JL; Allen, J; Packer, R; Bartels, U; Abdelbaki, MS. Pediatric Blood and Cancer. 2021; 68:e29172.

Venous thromboembolism in children with central nervous system tumors: Comparison of an institutional cohort to a national administrative database. Graham, RT; Coven, SL; Stanek, JR; Folta, A; Hollingsworth, EW; Finlay, JL; Kumar, R. Pediatric Blood and Cancer. 2021; 68:e28846.